Alzheimer's disease (AD), also referred to simply as Alzheimer's, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60% to 70% of cases of dementia.
Europe is estimated to grow at a rapid pace owing to the high prevalence of AD coupled with ever improving diagnostic capabilities. Asia Pacific is expected to witness the fastest growth over the forecast period owing to the rising disposable income level.

The global Alzheimer’s Therapeutics market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Alzheimer’s Therapeutics volume and value at global level, regional level and company level. From a global perspective, this report represents overall Alzheimer’s Therapeutics market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Alzheimer’s Therapeutics in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Alzheimer’s Therapeutics manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Pfizer
Merck &
Novartis AG
Eisai
H. Lundbeck A/S
AC Immune
TauRx Pharmaceuticals
Actavis plc.
Forest Laboratories
Teva Pharmaceuticals Industries
Janssen Pharmaceutical
GE healthcare
Eli Lilly And Company
DiaGenic ASA
VTV Therapeutics
Hoffman-La Roche
AstraZeneca
Daiichi Sankyo Company

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Donepezil
Memantine
Rivastigmine

Segment by Application
Early to Moderate Stages
Moderate to Severe Stages